Romero K, de Mars M, Frank D, Anthony M, Neville J, Kirby L, Smith K, Woosley RL.: et. al. et.al. et.al.

Author of the Paper:

Romero K, de Mars M, Frank D, Anthony M, Neville J, Kirby L, Smith K, Woosley RL.

Title of the Paper

The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases.

Journals

Clin Pharmacol Ther. 2009 Oct;86(4):365-7.

Address of correspondence

Coalition Against Major Diseases, Critical Path Institute, Tucson, Arizona, USA. kromero@c-path.org

Abstract

Aiming to emulate the successful accelerated development of HIV/AIDS drugs, the Critical Path Institute (C-Path), in collaboration with the Engelberg Center for Health Care Reform at the Brookings Institution, has formed the Coalition Against Major Diseases (CAMD). Members include 6 nonprofit groups representing patients' interests, 15 leading pharmaceutical companies, the US Food and Drug Administration (FDA), the European Medicines Agency (EMEA), 2 institutes of the National Institutes of Health (NIH)-the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS)-and representatives from academia. The coalition's purpose is to transform the drug development paradigm for neurodegenerative diseases and serve as a model for other major diseases.

Source: PubMed Abstract